PMC9617722_01
Clinical course of the disease. The diagram shows the clinical severity of dysphagia and weakness of the limbs from the onset of Guillain-Barre syndrome on day 1. The arrows indicate Guillain-Barre syndrome treatment with intravenous immunoglobulin (white) and intravenous methylprednisolone (black). On day 7, he showed severe muscle weakness in his neck and extremities, dysphagia, and respiratory difficulties. Thereafter, each symptom improved, and he was discharged on day 40 with minimal muscle fatigue. Abbreviations: IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; SARS-CoV-2 RNA, severe acute respiratory syndrome coronavirus 2 ribonucleic acid.
CRINM2022-6837851.001.jpg
PMC9617722_01_CRINM2022-6837851.001.jpg
fig1
He was discharged on day 40 with minimal muscle fatigue (Figure 1).